Table 3.
Treatment Phase and Oncological Follow-Up. Quality Indicators (2013)g
| Rectal Cancer | Center A |
Center B |
Center C |
Total ICO |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | n | % | P | ||
| Treatment phase | ||||||||||
| Distribution of patients according to treatment received | Chemo + concomitant RT + surgery | 39 | 97.5 | 37 | 92.5 | 37 | 92.5 | 113 | 94.2 | 0.225 |
| RT + surgery | 1 | 2.5 | 3 | 7.5 | 1 | 2.5 | 5 | 4.2 | ||
| RT + chemo | 2 | 5.0 | 2 | 1.7 | ||||||
| Type of radiotherapy | SCRT | 8 | 20.0 | 4 | 10.0 | · | · | 12 | 10.0 | 0.012* |
| LCRT | 32 | 80.0 | 36 | 90.0 | 40 | 100 | 108 | 90.0 | ||
| Total prescribed dose (Gy) | SCRT (25.00 Gy) | 8 | 20.0 | 4 | 10.0 | · | · | 12 | 10.0 | <0.001* |
| LCRT (45.00 Gy) | · | · | 36 | 90.0 | · | · | 36 | 30.0 | ||
| LCRT (50-54 Gy) | 32 | 80 | 0 | 0 | 40 | 100 | 72 | 60 | ||
| Treatment technique indicated | 3D | 37 | 92.5 | 40 | 100 | 40 | 100 | 117 | 97.5 | 0.188 |
| VMAT | 1 | 2.5 | · | · | · | · | 1 | .8 | ||
| IMRT | 2 | 5.0 | · | · | · | · | 2 | 1.7 | ||
| Percentage of patients completing planned treatment (dose) | Yes | 39 | 97.5 | 38 | 95.0 | 39 | 97.5 | 116 | 96.7 | 0.772 |
| No | 1 | 2.5 | 2 | 5.0 | 1 | 2.5 | 4 | 3.3 | ||
| Percentage of patients suffering interruptions according to the days treatment was prolonged (LCRT) | <3 days | 12 | 37.5 | 19 | 52.7 | 31 | 77.5 | 62 | 57.4 | 0.006* |
| 3-5 days | 12 | 37.5 | 11 | 30.5 | 9 | 22.5 | 32 | 29.6 | ||
| 6-10 days | 8 | 25.0 | 3 | 8.3 | 0 | 0 | 11 | 10.2 | ||
| >10 days | 0 | 0.0 | 3 | 8.3 | 0 | 0 | 3 | 2.8 | ||
| Percentage of patients undergoing restaging MRI | Yes | 8 | 20.0 | 0 | 0.0 | 31 | 77.5 | 39 | 32.5 | 0.001* |
| No | 32 | 80.0 | 40 | 100.0 | 9 | 22.5 | 81 | 67.5 | ||
| Percentage of patients with indication for surgical treatment following primary treatment (chemo and/or RT) | Yes | 39 | 97.5 | 40 | 100.0 | 37 | 92.5 | 116 | 96.7 | 0.087 |
| No | 3 | 7.5 | 3 | 2.5 | ||||||
| Missing⁎ | 1 | 2.5 | 1 | .8 | ||||||
| Percentage of patients according to radial margin result (ypCRM) | Positive | 1 | 2.6 | 1 | 2.5 | 3 | 8.1 | 5 | 4.3 | 0.001* |
| Negative | 28 | 71.8 | 15 | 37.5 | 28 | 75.7 | 71 | 61.2 | ||
| Missing⁎ | 10 | 25.6 | 24 | 60.0 | 6 | 16.2 | 40 | 34.5 | ||
| Percentage of patients undergoing surgery in ICO who had been previously presented in multidisciplinary committee to assess response to primary treatment | Yes | 8 | 100 | 23 | 69.7 | 21 | 72.4 | 52 | 74.3 | |
| No | 10 | 30.3 | 8 | 27.6 | 18 | 25.7 | 0.203 | |||
| Follow-Up Phase | ||||||||||
| Percentage of patients experiencing serious (>grade II) RT-related adverse effects | Yes | 1 | 2.5 | 3 | 7.5 | 2 | 5.0 | 6 | 5.0 | 0.591 |
| No | 39 | 97.5 | 37 | 92.5 | 38 | 95.0 | 114 | 95.0 | ||
| Percentage of patients with recorded follow-up in ICO | Yes | 36 | 90.0 | 37 | 92.5 | 39 | 97.5 | 112 | 93.3 | 0.392 |
| No | 4 | 10.0 | 3 | 7.5 | 1 | 2.5 | 8 | 6.7 | ||
Chemo, chemotherapy; RT, radiotherapy; VMAT, volumetric arc therapy; IMRT, intensity-modulated radiation therapy.
g
No data found in the medical records.